This EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.
Key topics of discussion include:
Interaction between alcohol and cardiometabolic risks
Stigma and its impact on patient care
Identifying at-risk patients with clinical markers
Emerging therapies and research opportunities
Faculty
Aleksander Krag (Moderator)
Fredrik Åberg (Faculty)
Maru Rinella (Faculty)
Maja Thiele (Faculty)
This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.
Podden och tillhörande omslagsbild på den här sidan tillhör European Association for the Study of the Liver. Innehållet i podden är skapat av European Association for the Study of the Liver och inte av, eller tillsammans med, Poddtoppen.
